Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.

Chang, Dwan-Ying; Ma, Wei-Li; Lu, Yen-Shen

Chang, Dwan-Ying; Ma, Wei-Li; Lu, Yen-Shen.

Afiliación

Chang DY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Ma WL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Lu YS; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.

Ther Clin Risk Manag ; 17: 193-207, 2021.

Article en En | MEDLINE | ID: mdl-33707948

Palabras clave

HR+/HER2− advanced/metastatic breast cancer; PIK3CA mutation test; alpelisib PI3K alpha-selective inhibitor; prognosis; survival benefit; toxicity management

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Ther Clin Risk Manag Año: 2021 Tipo del documento: Article País de afiliación: Taiwán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Ther Clin Risk Manag Año: 2021 Tipo del documento: Article País de afiliación: Taiwán